Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2011 to 2025 of 8215 results

  1. Surovatamig for treating relapsed or refractory B-cell acute lymphoblastic leukaemia after 2 or more lines of treatment in people 12 years and over [ID6630]

    Awaiting development Reference number: GID-TA11837 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Surovatamig for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more lines of treatment [ID6631]

    Awaiting development Reference number: GID-TA11849 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Mosunetuzumab with lenalidomide for treating relapsed or refractory follicular lymphoma after 1 or more systemic treatments [ID6655]

    Awaiting development Reference number: GID-TA11867 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Ravulizumab for preventing kidney events in people with chronic kidney disease at high risk after a cardiopulmonary bypass [ID6632]

    Awaiting development Reference number: GID-TA11841 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Somapacitan for treating growth failure caused by Turner syndrome in people 2 to 17 years [ID6621]

    Awaiting development Reference number: GID-TA11821 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Zilugisertib for preventing new heterotopic ossification lesions caused by fibrodysplasia ossificans progressiva in people 12 years and over [ID6637]

    Awaiting development Reference number: GID-TA11840 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Sibeprenlimab for treating IgA nephropathy [ID6604]

    Awaiting development Reference number: GID-TA11668 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Isatuximab in combination for maintenance treatment of newly diagnosed multiple myeloma after an autologous stem cell transplant [ID6639]

    Awaiting development Reference number: GID-TA11846 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Zilucoplan for treating antibody positive generalised myasthenia gravis [ID4008]

    In development Reference number: GID-TA11096 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Ex-situ machine perfusion devices for deceased donor liver transplants

    In development Reference number: GID-HTE10066 Expected publication date:  20 August 2026

    Health technology evaluations
    In development

  11. Epcoritamab + R-CHOP for Diffuse large B-cell lymphoma (DLBCL) [TSID12334]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  12. Type 2 diabetes in adults: management (medicines update)

    In development Reference number: GID-NG10336 Expected publication date:  18 February 2026

    NICE guideline
    In development

  13. Gilteritinib + daunorubicin + cytarabine for Acute myeloid leukaemia (AML) [TSID12331]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  14. Mavorixafor for treating WHIM syndrome [ID3946]

    Awaiting development Reference number: GID-TA10833 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Sonesitatug vedotin for previously treated metastatic claudin 18.2-positive gastric or gastro-oesophageal junction adenocarcinomar [ID6669]

    Awaiting development Reference number: GID-TA11879 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development